THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
March 18, 2024 07:30 ET | Abeona Therapeutics Inc.
CLEVELAND, March 18, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the full year of 2023 and provided an update on progress toward achieving...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 05, 2024 07:30 ET | Abeona Therapeutics Inc.
CLEVELAND, March 05, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity...
PMV main logo.png
PRISM MarketView Highlights Work of Emerging Companies on Rare Disease Day
February 29, 2024 09:54 ET | PRISM MarketView
PRISM MarketView Highlights Work of Emerging Companies on Rare Disease Day
Logo.png
Gene Therapies In Ophthalmology Clinical Trial Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
February 19, 2024 13:00 ET | DelveInsight Business Research LLP
New York, USA, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Gene Therapies In Ophthalmology Clinical Trial Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment |...
Artios-Logo_Dark_Large_RGB-01.png
Artios Pharma Strengthens Financial Leadership with Appointment of Christine Silverstein as Chief Financial Officer
February 07, 2024 08:00 ET | Artios Pharma, Inc.
CAMBRIDGE, United Kingdom and NEW YORK, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Artios Pharma Limited (“Artios”), clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 01, 2024 16:05 ET | Abeona Therapeutics Inc.
CLEVELAND, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)
February 01, 2024 07:30 ET | Abeona Therapeutics Inc.
- On track for PDUFA target action date of May 25, 2024 - CLEVELAND, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced, as part of the review process by the...
22157.jpg
Hydrogels Pipeline: Strategic Analysis, Regulatory Insights, and Clinical Trial Data Unveiled in Comprehensive Industry Overview
January 23, 2024 17:58 ET | Research and Markets
Dublin, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The "Hydrogels Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies" report has been added to ResearchAndMarkets.com's...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Announces $50 Million Credit Facility
January 08, 2024 07:30 ET | Abeona Therapeutics Inc.
CLEVELAND, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it has entered into a $50 million credit facility with the Avenue Venture Opportunities...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 15, 2023 07:30 ET | Abeona Therapeutics Inc.
CLEVELAND, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity...